Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

The New York Times – Business:

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.

Gina Kolata and Rebecca Robbins
Author: Gina Kolata and Rebecca Robbins

This post first appeared in The New York Times – Business. Read the original article.

Written by

Gina Kolata and Rebecca Robbins

in

Clinical Trials, Drugs (Pharmaceuticals), Pancreas, Pancreatic Cancer, Research, Tumors
←Senate Democrats press Netanyahu on ‘surge’ in West Bank violence
United Airlines unveils major international expansion→

More posts

  • The Capitol Hired You To Rebrand “The Hunger Games” Fashion For 2026. What Could Possibly Go Wrong?

  • ‘Love is Blind’ Exes Jax Guelli, Scott ‘Stew’ Stewart Spotted After Reunion Release

  • California man found guilty of starting deadly Palisades Fire

  • Which “Shrek” Character Are You Most Like In The Mind, Body, And Soul?

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube